Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: biowa who wrote (4738)	4/23/1998 4:08:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 9719

biowa, As is fairly obvious from the size of LGND's pipeline, they are grossly under funded. In house they seem to be focused on rexinoids and androgen antagonists. Their partner for some of the progesterone analogs is AHP, who is more focused on the estrogen side (they have a $1 Billion Premarin market to protect). I'm not sure when progesterone analogs are slated to enter the clinic, but as can be seen from the table, many compounds should be just about finished with pre-clinical testing and are ready for IND filing.